Argenx SE - Company Profile
Powered by 
All the sales intelligence you need on Argenx SE in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Argenx SE fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Argenx SE.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Argenx SE (Argenx) is an immunology company that develops human antibody products for autoimmune diseases. The company's product includes VYVGART which is used to treat generalized myasthenia gravis and primary immune thrombocytopenia; empasiprubart for multifocal motor neuropathy, delayed graft function and chronic inflammatory demyelinating polyneuropathy; and others. It also offers pipeline products including ARGX-119 which targets congenital myasthenic syndrome and amyotrophic lateral sclerosis; ARGX-109, ARGX-121, ARGX-213 and ARGX-220. The company leverages SIMPLE Antibody Platform, NHANCE, ABDEG and POTELLIGENT technology platform. It operates offices in the Netherlands, the US, Japan, Switzerland, Canada, Italy, Spain, the UK and Belgium. Argenxis headquartered in Amsterdam, Noord-Holland, the Netherlands.
Headquarters
Netherlands
Address
Laarderhoogtweg 25, Amsterdam, Noord-Holland, 1101EB
Website
www.argenx.com
Telephone
31 10 7038441
No of Employees
1,599
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARGX (EBR)
Revenue (2024)
$4.2B
89.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
55.1%
(2024 vs 2023)
Market Cap*
$56.4B
Net Profit Margin (2024)
XYZ
-18.2%
(2024 vs 2023)
* As of and is in US$
Argenx SE premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | VYVGART |
| VVVGART: | SIMPLE Antibody |
| Generalized Myasthenia Gravis | ABDEG |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In December, the company received approval from Japan’s Ministry of Health, Labour, and Welfare for VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). |
| 2024 | Regulatory Approval | In November, the company and Zai Lab received approval from the National Medical Products Administration of China for the supplemental biologics license application for VYVGART Hytrulo 1,000 mg vial to treat chronic inflammatory demyelinating polyneuropathy in adults. |
| 2024 | Contracts/Agreements | In March, the company entered into an agreement with FUJIFILM Diosynth Biotechnologies to provide drug products and finished goods services for efgartigimod in patients with severe autoimmune disease. |
Competitor Comparison
| Key Parameters | Argenx SE | AbbVie Inc | GSK plc | Amgen Inc | Biogen Inc |
|---|---|---|---|---|---|
| Headquarters | Netherlands | United States of America | United Kingdom | United States of America | United States of America |
| City | Amsterdam | North Chicago | London | Thousand Oaks | Cambridge |
| State/Province | Noord-Holland | Illinois | England | California | Massachusetts |
| No. of Employees | 1,599 | 57,000 | 66,841 | 31,500 | 7,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tim Van Hauwermeiren | Chairman | Executive Board | 2026 | 52 |
| Donald deBethizy | Vice Chairman | Executive Board | 2023 | 74 |
| Karen Massey | Director; Chief Executive Officer | Executive Board | 2026 | 46 |
| Karl Gubitz | Chief Financial Officer | Senior Management | 2021 | 55 |
| Luc Truyen | Chief Medical Officer | Senior Management | 2022 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer